GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Arcadia Biosciences Inc (NAS:RKDA) » Definitions » Earnings Power Value (EPV)

Arcadia Biosciences (Arcadia Biosciences) Earnings Power Value (EPV) : $-439.25 (As of Dec23)


View and export this data going back to 2015. Start your Free Trial

What is Arcadia Biosciences Earnings Power Value (EPV)?

As of Dec23, Arcadia Biosciences's earnings power value is $-439.25. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Arcadia Biosciences Earnings Power Value (EPV) Historical Data

The historical data trend for Arcadia Biosciences's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcadia Biosciences Earnings Power Value (EPV) Chart

Arcadia Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Power Value (EPV)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,179.12 -1,535.43 -886.70 -918.18 -439.25

Arcadia Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -918.18 -695.07 -443.28 -442.74 -439.25

Competitive Comparison of Arcadia Biosciences's Earnings Power Value (EPV)

For the Packaged Foods subindustry, Arcadia Biosciences's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcadia Biosciences's Earnings Power Value (EPV) Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Arcadia Biosciences's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Arcadia Biosciences's Earnings Power Value (EPV) falls into.



Arcadia Biosciences Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

Arcadia Biosciences's "Earning Power" Calculation:

Average of Last 20 Quarters Last Quarter
Revenue 6.21
DDA 0.53
Operating Margin % -933.35
SGA * 25% 4.24
Tax Rate % -0.08
Maintenance Capex 1.06
Cash and Cash Equivalents 11.64
Short-Term Debt 0.85
Long-Term Debt 0.16
Shares Outstanding (Diluted) 1.36

1. Start with "Earnings" not including accounting adjustments (one-time charges not excluded unless policy has changed). "Earnings" are "Operating Income.

2. Look at average margins over a business/Industry cycle: Average Operating Margin = -933.35%

To normalize margins and eliminate the effects on profitability of valuing the firm at different points in the business cycle, it is usually best to take a long-term average of operating margins. Ideally this would be as long as 10 years and include at least one economic downturn. However, since most of companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year margin.

3. Multiply average margins by sustainable revenues and then adjust for maintenance SGA. This yields "normalized" EBIT:

To be conservative, GuruFocus uses an average of the 5 year revenues as the sustainable revenue.
EPV analysis recognises that part of SG&A expenditure is made to maintain and replace the existing assets, while part is made to grow sales. Since EPV is only interested in what it costs a going concern to maintain its existing asset base, it adds back a percentage of SG&A (between 15% and 50% - this is a matter of judgment and industry knowledge) to make up for the fact that some of this expenditure went to fund growth and shouldn't be accounted for. To start off, we assume 25% for the sake of prudence.
Sustainable Revenue = $6.21 Mil, Average Operating Margin = -933.35%, Average Adjusted SGA = 4.24,
therefore "Normalized" EBIT = Sustainable Revenue * Average Operating Margin + Average Adjusted SGA = 6.21 * -933.35% +4.24 = $-53.6989232 Mil.

4. Multiply by one minus Average Tax Rate (NOPAT):

Same as average operating margin calculation, GuruFocus takes an average of the 5 years tax rates.
Average Tax Rate = -0.08%, and "Normalized" EBIT = $-53.6989232 Mil,
therefore After-tax "Normalized" EBIT = "Normalized" EBIT * ( 1 - Average Tax Rate ) = -53.6989232 * ( 1 - -0.08% ) = $-53.741345349328 Mil.

5. Add back Excess Depreciation (after tax at 1/2 average tax rate). This yields "normalized" Earnings:

Excess Depreciation = Average DDA * % of Excess Depreciation (after tax at 1/2 average tax rate) = 0.53 * 0.5 * -0.08% = $-0.000210693 Mil.
"Normalized" Earnings = After-tax "Normalized" EBIT + Excess Depreciation = -53.741345349328 + -0.000210693 = $-53.741556042328 Mil.

6. Adjusted for Maintenance Capital Expenditure:

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Third, calculate Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
Fourth, GuruFocus uses an average of the 5 year maintenance capital expenditures as maintenance CAPEX.
Arcadia Biosciences's Average Maintenance CAPEX = $1.06 Mil *.
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

7. Investors require a return of "WACC" for the risk they are taking: WACC = 9%

8. Arcadia Biosciences's current cash and cash equivalent = $11.64 Mil.
Arcadia Biosciences's current interest bearing debt = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation = 0.16 + 0.85 = $1.007 Mil.
Arcadia Biosciences's current Shares Outstanding (Diluted Average) = 1.36 Mil.

Arcadia Biosciences's Earnings Power Value (EPV) for Dec23 is calculated as:

EPV = ( ( Norm. Earnings-Maint. CAPEX *) / WACC + CashandEquiv - Int. Bearing Debt ) / Shares Outstanding (Diluted Average)
= ( ( -53.741556042328 - 1.06)/ 9%+11.64-1.007 )/1.36
=-439.25

Margin of Safety (EPV)=( Earnings Power Value (EPV)-Current Price )/Earnings Power Value (EPV)
=( -439.24625585192-1.955 )/-439.24625585192
= N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.


Arcadia Biosciences  (NAS:RKDA) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Arcadia Biosciences Earnings Power Value (EPV) Related Terms

Thank you for viewing the detailed overview of Arcadia Biosciences's Earnings Power Value (EPV) provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcadia Biosciences (Arcadia Biosciences) Business Description

Traded in Other Exchanges
Address
5950 Sherry Lane, Suite 215, Dallas, TX, USA, 75225
Arcadia Biosciences Inc is a producer and marketer of innovative, plant-based food and beverage products. It is engaged in science-based approaches to developing high-value crop improvements primarily in wheat, soy, and hemp, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health, and wellness products, and their viability for industrial applications. The company's consumer brands in the food, beverage, and body care categories include GoodWheat high-fiber pasta, Zola coconut water, ProVault topical pain relief, and SoulSpring bath and body care.
Executives
Thomas J. Schaefer officer: Chief Financial Officer 202 COUSTEAU PLACE STE 105, DAVIS CA 95618
Stanley Jr Jacot officer: Chief Executive Officer 202 COUSTEAU PLACE STE 105, DAVIS CA 95618
Pamela Haley officer: Chief Financial Officer 202 COUSTEAU PLACE, DAVIS CA 95618
Laura Pitlik officer: Chief Marketing Officer 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Chris Cuvelier officer: Chief Growth Officer 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Deborah D Carosella director 3603 HAVEN AVE, SUITE E, MENLO PARK CA 94025
Matthew T Plavan officer: Chief Financial Officer C/O THERMOGENESIS CORP., 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Randall Shultz officer: Chief Technology Officer 4222 E. THOMAS ROAD, SUITE 320, PHOEBIIX AZ 85018
Sarah Reiter officer: Chief Commercial Officer 202 COUSTEAU PLACE, DAVIS CA 95618
Lilian Shackelford Murray director 228 BEACH ROAD, BELVEDERE CA 94920
Kevin Comcowich director C/O ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Albert D. Bolles director CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
Eric J. Rey director, officer: President and CEO ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Zhongjin Lu officer: VP Product Development ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Amy Yoder director C/O SPECTRUM BRANDS, INC., 6 CONCOURSE PARKWAY, SUITE 3300, ATLANTA GA 30328